England Approves First New Ovarian Cancer Drug in 20 Years

Women facing one of the toughest ovarian cancer diagnoses just got their first new treatment option in over 20 years.

NHS England has approved Elahere, a life-extending drug for patients whose advanced ovarian cancer no longer responds to standard chemotherapy. Up to 400 women annually can now access this treatment, offering hope where options were severely limited.

The approval targets a specific group: women with ovarian, peritoneal, or fallopian tube cancer that contains a protein called folate receptor-alpha. When platinum-based chemotherapy stops working for these patients, they've had virtually nowhere else to turn until now.

Elahere works differently than traditional treatments. The drug combines a targeted antibody that hunts down cancer cells with a molecule that destroys them from within, like a guided missile seeking its target.

A global clinical trial involving eight NHS hospitals delivered promising results. Patients receiving Elahere lived an average of four months longer than those on chemotherapy alone. In more than one-third of patients, tumors shrank by at least 30 percent, compared to just 16 percent with standard chemotherapy.

The treatment comes as a drip every three weeks and causes fewer difficult side effects than traditional chemotherapy. For women watching their quality of life deteriorate under harsh treatments, this represents a significant improvement.

Ovarian cancer affects over 300,000 women worldwide each year. More than three-quarters are diagnosed at advanced stages when the disease is harder to treat. About 80 percent of advanced cases eventually stop responding to chemotherapy, leaving patients with few choices.

The Ripple Effect

This breakthrough extends beyond the treatment room. Rachel Downing from Target Ovarian Cancer called it "a hugely important moment" for families who've faced limited options for far too long. The approval signals renewed investment in ovarian cancer research after years of stagnation.

Victoria Clare, chief executive of charity Ovacome, emphasized the psychological relief this brings. Being told chemotherapy no longer works creates tremendous anxiety and uncertainty, especially when time matters most. Having another option at this critical stage offers patients and families something they desperately need: choice.

Professor Ruth Plummer, NHS England's national clinical lead for cancer drugs, described it as "the most significant breakthrough in NHS treatment for these hard-to-treat ovarian cancers in over two decades." The approval followed rigorous evaluation and a commercial agreement with drugmaker AbbVie to make the treatment accessible.

After 20 years of waiting, women with resistant ovarian cancer finally have reason for hope.